Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK

Diabetic Medicine

Volumn 22, Issue 9, 2005, Pages 1239-1245

  Roze, Stéphane ^a   Valentine, W J ^a   Zakrzewska, K E ^b   Palmer, A J ^a  

^a IQVIA   (United States)

^b Medtronic AG   (Switzerland)

Author keywords

Continuous subcutaneous insulin infusion; Cost effective; Costs; Insulin; Modelling; Multiple daily injection; Type 1 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; PEER REVIEW; QUALITY OF LIFE; SIMULATION; TREATMENT OUTCOME; UNITED KINGDOM; VALIDATION PROCESS;

ADULT; COHORT STUDIES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INJECTIONS; INSULIN; INSULIN INFUSION SYSTEMS; LIFE EXPECTANCY; MALE; PROGNOSIS; QUALITY OF LIFE;

EID: 24044470981     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01576.x     Document Type: Article

References (30)

1. Passa P. Diabetes trends in Europe. Diabetes Metab Res Rev 2002; 18: S3-S8.
2. Zhao HX, Stenhouse E, Soper C, Hughes P, Sanderson E, Baumer JH et al. Incidence of childhood-onset Type 1 diabetes mellitus in Devon and Cornwall, England, 1975-96. Diabet Med 1999; 16: 1030-1035.
3. Evans JM, MacDonald TM, Leese GP, Ruta DA, Morris AD. Impact of type 1 and type 2 diabetes on patterns and costs of drug prescribing: a population-based study. Diabetes Care 2000; 23: 770-774.
4. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 2002; 18: S14-20.
5. Lenhard MJ, Reeves GD. Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med 2001; 161: 2293-2300.
6. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002; 324: 705.
7. Palmer AJ, Roze S, Valentine W, Minshall M, Foos V, Lurati F et al. The CORE Diabetes Model: projecting long term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004; 20: S6-S26.
8. Palmer AJ, Roze S, Foos V, Lurati F, Ray J, Lammert M et al. Validation CORE Diabetes Model. Curr Med Res Opin 2004; 20: S27-S40.
9. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 2003; 26: 1079-1087.
10. Linkeschova R, Raoul M, Bott U, Berger M, Spraul M. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 2002; 19: 746-751.
11. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003; 289: 2254-2264.
12. Klein R, Moss S. A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 1995; 155: 745-754.
13. Benett IJ, Lambert C, Hinds G, Kirton C. Emerging standards for diabetes care from a city-wide primary care audit. Diabet Med 1994; 11: 489-492.
14. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study, 65). Diabet Med 2003; 20: 442-450.
15. Currie CJ, Morgan CL, Peters JR. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes Care 1998; 21: 42-48.
16. United Kingdom Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes. UKPDS 40 BMJ 1998; 317: 720-726.
17. NHS UK. Transplant Statistics 2002. (http://www.uktransplant. org.uk/ukt/statistics/yearly_statistics/yearly_kidney_statistics.jsp).
18. Ghatnekar O, Persson U, Willis M, Odegaard K. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001; 19: 767-778.
19. NICE: National Institute for Clinical Excellence. Technology appraisal. Guidance-No. 53. Guidance on the Use of Long-Acting Insuiln Analogues for the Treatment of Diabetes-Insulin Glargine. 12-1-2002.
20. James M, Turner DA, Broadbent DM, Vora J, Harding SP. Cost effectiveness analysis of screening for sight threatening diabetic eye disease. BMJ 2000; 320: 1627-1631.
21. OMNILABS (UK) Limited. Price List, effective October 2000, London 2000.
22. Scuffham P, Carr L. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabet Med 2003; 20: 586-593.
23. eMIMS. Monthly Index of Medical Specialities, www.emims.net, 2004.
24. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002; 22: 340-349.
25. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000; 38: 583-637.
26. Australian Institute of Health and Welfare. The Burden of Disease and Injury in Australia, 2003.
27. Carrington AL, Mawdsley SK, Morley M, Kincey J, Boulton AJ. Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract 1996; 32: 19-25.
28. Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003; 26: 2063-2068.
29. Hunink MG, Bult JR, de Vries J, Weinstein MC. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 1998; 18: 337-346.
30. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437-452.